Eric Dube, CEO of Travere Therapeutics, leads the company with extensive experience in the pharmaceutical industry. After earning his B.S. from Santa Clara University and a Ph.D. from Cornell University, he took the helm at Travere on January 4, 2019....
Eric Dube, CEO of Travere Therapeutics, leads the company with extensive experience in the pharmaceutical industry. After earning his B.S. from Santa Clara University and a Ph.D. from Cornell University, he took the helm at Travere on January 4, 2019. Before joining, he was the head of North America at ViiV Healthcare and held various senior roles at GlaxoSmithKline, focusing on respiratory and oncology drugs. During his time as CEO, Dube has guided Travere through challenges like COVID-19 while pushing for corporate goals related to drug development and patient outreach. Under his watch, the company's equity awards indicate a focus on long-term growth, with substantial stock options granted to him, aligning his success with that of the company. He has been proactive in enhancing shareholder value, which shows in his stock transactions, pulling multi-million dollar amounts throughout 2021. This reflects a deep commitment to not just lead the company but also personally invest in its future. Dube’s leadership mixes academic knowledge with practical experience, aiming to create effective therapies for patients in need.